phase 11 - Cancer Research UK launches 'outpatients' (oral)trial of breast and ovarian cancer drug (BRCA/serous cell type - AG-014699 known as Rucaparib or CO-338 - PARP inhibitor)

" Cancer Research UK’s Drug Development Office has re-launched a trial of a promising drug to treat inherited breast and ovarian cancer – but this time taken as a tablet by outpatients."
 
"Women with advanced breast or ovarian cancer with faults in the known high-risk BRCA1 or BRCA2 genes will receive the drug called AG-014699 (Rucaparib) – which belongs to a promising class of drugs called PARP inhibitors. The trial is also open to women with advanced serous ovarian cancer but unknown BRCA status."

"Notes to editors

The drug AG-014699 (also called Rucaparib or CO-338) was recently licenced to Clovis Oncology from Pfizer."